Simplifying Alzheimer's Disease Monitoring: A Novel Machine-Learning Approach to Estimate the Clinical Dementia Rating Sum of Box Changes Using the Mini-Mental State Examination and Functional Activities Questionnaire.

Journal: Journal of Alzheimer's disease : JAD
PMID: 38759009

Abstract

BACKGROUND: Primary outcome measure in the clinical trials of disease modifying therapy (DMT) drugs for Alzheimer's disease (AD) has often been evaluated by Clinical Dementia Rating sum of boxes (CDRSB). However, CDR testing requires specialized training and 30-50 minutes to complete, not being suitable for daily clinical practice.

Authors

  • Kenichiro Sato
    Department of Neuropathology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
  • Yoshiki Niimi
    Unit for Early and Exploratory Clinical Development, The University of Tokyo Hospital, Tokyo, Japan.
  • Ryoko Ihara
    Department of Neurology, Tokyo Metropolitan Institute for Geriatrics and Gerontology, Tokyo, Japan.
  • Kazushi Suzuki
    Division of Neurology, Internal Medicine, National Defense Medical College, Saitama, Japan.
  • Atsushi Iwata
    Department of Neurology, Tokyo Metropolitan Institute for Geriatrics and Gerontology, Tokyo, Japan.
  • Takeshi Iwatsubo
    Department of Neuropathology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.

Keywords

External Resources

Popular Topics
Recent Journals